Monitor for UPSTREAM MG topline data in 1H27 and potential regulatory filings for telitacicept in US/EU/Japan. Cash runway into early 2029 reduces near-term dilution risk, but the stock remains binary on clinical outcomes.
Price Chart
Executive Summary
Vor Bio reported Q2 2026 financial results with net loss of $62.8M, cash of $466.1M (plus $48.4M from July ATM sales), and provided pipeline updates for telitacicept. Phase 3 UPSTREAM MG and UPSTREAM SjD trials are enrolling with topline data expected in 1H27. As a pre-revenue clinical-stage biotech, the filing is a routine quarterly update with no material financial surprises.
Key Facts
- Cash, cash equivalents and marketable securities were $466.1M as of June 30, 2026, with $48.4M additional net proceeds from ATM sales in July 2026, providing runway into early 2029.
- Net loss for Q2 2026 was $62.8M, compared to $1,573.7M in Q2 2025 (decrease primarily due to change in fair value of liability-classified warrants).
- R&D expenses were $25.9M vs $261.5M in Q2 2025; G&A expenses were $21.9M vs $12.8M.
- Enrollment ongoing in global Phase 3 UPSTREAM MG trial for generalized myasthenia gravis and UPSTREAM SjD trial for primary Sjögren's disease, with topline data from UPSTREAM MG anticipated in 1H27.
- Telitacicept received commercial approvals in China for Sjögren's disease and IgA nephropathy; Phase 3 TELIGAN results published in NEJM.
- Appointed David Zaccardelli to Board of Directors.
Financial Impact
Net loss of $62.8M; cash position of $466.1M plus $48.4M ATM proceeds; no revenue reported.
Risk Factors
- Clinical trial failure or delay in UPSTREAM MG or UPSTREAM SjD
- Regulatory setbacks in US/EU/Japan despite China approvals
- Competition from other BAFF/APRIL inhibitors in autoimmune indications
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3342846 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | Press Release | $23.37 $23.24 | ▼ −0.58% | ▲ +0.48% | $18.47 (−20.97%) |
Jul 9, 2026 12w ago | 3 | $19.14 $23.67 | ▲ +23.67% | ▲ +21.24% | $18.47 (−3.50%) |
Jun 11, 2026 16w ago | Institutional Cluster | $14.09 $19.75 | ▲ +40.17% | ▲ +38.28% | $18.47 (+31.09%) |
Jun 8, 2026 16w ago | Press Release | $13.29 $20.10 | ▲ +51.24% | ▲ +49.61% | $18.47 (+38.98%) |
May 7, 2026 21w ago | EFFECT | $16.08 $13.44 | ▼ −16.42% | ▼ −19.55% | $18.47 (+14.86%) |
Apr 27, 2026 22w ago | S-3 | $14.38 $14.10 | ▼ −1.95% | ▼ −7.42% | $18.47 (+28.44%) |
Apr 27, 2026 22w ago | DEFA14A | $14.38 $14.10 | ▼ −1.95% | ▼ −7.42% | $18.47 (+28.44%) |
Mar 27, 2026 27w ago | Press Release | $14.48 $14.12 | ▼ −2.49% | ▼ −15.23% | $18.47 (+27.56%) |
Mar 23, 2026 27w ago | Press Release | $12.15 $15.32 | ▲ +26.09% | ▲ +17.19% | $18.47 (+52.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access